BioMarin Pharmaceutical stock holds near its 52-week low

Published on 09/22/2026 at 23:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin Pharmaceutical stock closed at USD 63.94 on September 18, 2026, near its USD 60.63 52-week low. J.P. Morgan kept a Buy rating at USD 86.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin Pharmaceutical stock (ISIN US09061G1013) closed at USD 63.94 on Nasdaq on September 18, 2026, leaving the shares close to their 52-week low of USD 60.63. The same market snapshot showed a 52-week high of USD 70.98, volume of 4.46 million shares and a market capitalization of USD 12.38 billion.

Analyst target stays above price

According to The Globe and Mail on September 22, 2026, J.P. Morgan analyst Jessica Fye maintained a Buy rating and a USD 86.00 price target for BioMarin. The target stood USD 22.06 above the September 18 closing price, while the report cited a consensus target of USD 93.15 and a Strong Buy consensus rating.

The comparison is material because the consensus target was USD 29.21 above the latest close, or 45.7 percent higher when calculated against USD 63.94. The market data also showed a price-to-earnings ratio of 172.81, placing valuation alongside pipeline execution as a central issue for the shares.

Second quarter delivered an earnings beat

BioMarin reported USD 1.20 in earnings per share for its quarter announced on August 6, 2026, according to MarketBeat. That result exceeded the consensus estimate of USD 0.95 by USD 0.25, while quarterly revenue increased 20.0 percent year over year.

The earnings comparison provides a concrete counterweight to the share price position. A USD 0.25 EPS beat and 20.0 percent revenue growth indicate operating progress in the reported quarter, but the stock still closed only USD 3.31 above its 52-week low, leaving the market focused on whether growth can support the high earnings multiple.

Rare disease portfolio remains central

BioMarin develops and commercializes therapies for rare and serious diseases, according to the company description carried by MarketBeat. A September 22, 2026 report summarized management plans around the integration of Amicus Therapeutics, additional business development and growth prospects for VOXZOGO and other rare-disease programs, as reported by Ground News.

Stock remains below yearly high

At USD 63.94 on Nasdaq as of September 18, 2026, BioMarin trades USD 7.04 below its 52-week high of USD 70.98 and USD 3.31 above its 52-week low of USD 60.63. The dated price, the 20.0 percent revenue increase and the USD 1.20 EPS result define the current risk and opportunity balance without turning the analyst targets into a forecast.